Can-Fite BioPharma’s Piclidenoson Shows Promise in Vascular Dementia Treatment

Can-Fite BioPharma ( (CANF) ) has shared an update.

On July 28, 2025, Can-Fite BioPharma Ltd. announced a breakthrough study from UCLA demonstrating the efficacy of its drug Piclidenoson in treating vascular dementia. Conducted by Dr. S. Thomas Carmichael, the study showed that Piclidenoson restored tissue integrity and behavioral function in a vascular dementia mouse model. Vascular dementia, the second most common cause of dementia after Alzheimer’s, currently lacks FDA-approved therapies. With an aging population and increasing diagnosis, the global market for vascular dementia is estimated at $6 billion in 2025. Piclidenoson, a selective A3 adenosine receptor agonist, could fulfill a significant unmet need in this market, potentially capturing a large share due to its neuroprotective properties and ability to improve vascular health.

The most recent analyst rating on (CANF) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Can-Fite BioPharma stock, see the CANF Stock Forecast page.

Spark’s Take on CANF Stock

According to Spark, TipRanks’ AI Analyst, CANF is a Neutral.

Can-Fite BioPharma’s overall stock score reflects significant financial challenges and a bearish technical outlook. The company’s negative profitability, declining revenues, and reliance on external financing are major concerns. Technical indicators suggest caution, while valuation metrics indicate ongoing losses, affecting investor confidence.

To see Spark’s full report on CANF stock, click here.

More about Can-Fite BioPharma

Can-Fite BioPharma Ltd. is a clinical-stage biotechnology company focused on developing proprietary small molecule drugs for the treatment of cancer and inflammatory diseases. The company is advancing its lead drug candidate, Piclidenoson, which has shown promising results in Phase 3 trials for psoriasis, and Namodenoson, which is being evaluated for hepatocellular carcinoma and other cancers. Can-Fite’s drugs have demonstrated a compelling safety profile in clinical studies involving over 1,600 patients.

Average Trading Volume: 111,875

Technical Sentiment Signal: Sell

Current Market Cap: $14.3M

Learn more about CANF stock on TipRanks’ Stock Analysis page.